What are contract research organizations?

TL;DR

CB2 Insights is a research and technology platform focused on mainstreaming cannabis into traditional healthcare, offering clinical operations, technology and analytics, and clinical research services.

Transcript

my name is pride shaker I'm the CEO of CV 2 insights trading on the CSC under ticker symbol C VIII CB 2 insights is a research and technology platform specializing in the medical cannabis sector our goal is really mainstreaming cannabis into traditional healthcare we operate under three primary divisions clinical operations where we own and operate... Read More

Key Insights

• 😷 CB2 Insights operates in the medical cannabis sector, specializing in clinical operations, technology and analytics, and clinical research.
• 😷 They own and operate a network of medical centers, representing 35 clinics across the U.S., for medical cannabis evaluations.
• ❓ CB2 Insights offers a proprietary clinical trial management software, accumulating over 500,000 patient interactions and clinically validated outcomes.
• 😷 The European and South American markets present significant opportunities for CB2 Insights to expand their medical cannabis-focused infrastructure.
• 😷 Contract research organizations (CROs) play a crucial role in facilitating clinical trials, preclinical trials, and post-market data reporting in the medical cannabis industry.
• 😷 CB2 Insights aims to fill the gap in efficacy data for medical cannabis products and help drug manufacturers differentiate their offerings.
• 💪 They are investing in infrastructure and building a strong pipeline of potential customers globally.

Questions & Answers

Q: What are the three primary divisions of CB2 Insights?

CB2 Insights has three primary divisions: clinical operations, technology and analytics, and clinical research. In clinical operations, they own and operate a network of medical centers specializing in medical cannabis evaluations. In technology and analytics, they offer a proprietary clinical trial management software for capturing data in the medical cannabis sector. In clinical research, they provide full-service contract research organization (CRO) services for clinical trials and research.

Q: Why is the European market a great opportunity for CB2 Insights?

The European market, particularly the South American markets, presents a great opportunity for CB2 Insights as they expand into a medical cannabis-focused infrastructure. These markets have prescriptive regulations where patients are prescribed specific doses of specific products, providing an ideal environment for evidence-based outcomes and understanding medical cannabis efficacy.

Q: What is the role of a contract research organization (CRO) in the medical cannabis industry?

A contract research organization (CRO) assists drug manufacturers and research organizations in the clinical trial process, from formulation to commercialization. CROs facilitate clinical trials, preclinical trials, post-marketing data reporting, and achieve faster and more effective results than pharma companies or academic organizations alone.

Q: How does CB2 Insights address the need for efficacy data in the medical cannabis industry?

CB2 Insights recognizes the gap in efficacy data for medical cannabis products. They aim to help drug manufacturers keep their products on the shelves by investing in research and providing the infrastructure, people, and services needed to develop substantial data. This data not only improves education and post-commercialization, but also differentiates products in the market.

Summary & Key Takeaways

• CB2 Insights is a research and technology platform in the medical cannabis sector, with three primary divisions: clinical operations, technology and analytics, and clinical research.

• They own and operate one of the largest networks of medical centers specializing in medical cannabis evaluations in the U.S., representing 35 clinics and serving over 100,000 active patients annually.

• CB2 Insights provides a proprietary clinical trial management software for researchers and organizations, accumulating over 500,000 patient interactions and clinically validated outcomes in the medical cannabis sector.